The molecular pathophysiology underlying keloid scar formation and progression is complex and poorly understood. Both genetic factors (including ethnicity) and environmental factors such as trauma are known to be important. 5, 7, 8 More recently, interest in the possible roles of epigenetic mechanisms in this disease has developed.
Epigenetic control of gene expression and its role in disease is an area of increasing interest and substantial complexity. 9, 10 Epigenetics encompasses any mechanism of modulation of gene expression other than changes to the DNA sequence itself. Some epigenetic changes, such as DNA methylation, alter the structure of the DNA and are heritable upon cell division, providing a mechanism for sustained changes to cell phenotype. 11, 12 Other epigenetic mechanisms, such as noncoding RNAs predominantly affect phenotype more transiently. 13 However, our understanding of epigenetics continues to change and in particular the dynamic changes to DNA methylation, histone acetylation and non-coding RNAs in the control of cell phenotypes. As understanding of the array of epigenetic mechanisms has increased so has the interest in investigating these mechanisms for their roles in disease. There is strong evidence that epigenetic mechanisms are important in a large number of both physiological and pathological conditions, from development to tumourigenesis.
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Here we have reviewed the current literature that provides evidence for a role of epigenetic changes in the pathophysiology of keloid scarring. We have focused on changes to DNA structure through methylation and histone modification as well as the role of non-coding RNAs.
| METHODS
We carried out a comprehensive search for articles related to epigenetic mechanisms in keloid scarring using databases including PubMed, Embase and China National Knowledge Infrastructure (CNKI). The key words used were epigenetics, DNA methylation, histone modification, non-coding RNA, long non-coding RNA, circular RNA, microRNA and keloid. For this review, original articles were further identified by manual searching. Articles published up to July 2016 were included in this review with the focus on key animal and human studies related to keloid scar.
| GENETICS OF KELOID SCARRING

| Advances in genetic studies of keloid scarring
Family survey data show that this disease may be autosomal dominant inheritance with incomplete penetrance. However, keloid scarring does not follow a simple Mendelian monogenic disease, it tends to be a polygenic disease.
14-17
Using a genome-wide association study (GWAS) approach in the Japanese population, Nakashima M et al. identified a significant relationship between keloid scarring and four single nucleotide polymorphisms (SNPs) in three chromosomal regions: rs873549 at 1q41, rs940187
and rs1511412 at 3q22.3 and rs8032158 at 15p21.3. 18 Through using the Sequenom MassArray system, another study observed that three 
| Limitations of genetic studies on keloid scarring
In recent studies, GWAS approaches have identified some susceptibility genes that promote fibroblast differentiation and activation. epigenetic mechanisms may also play a pivotal role. 28, 29 Epigenetic modification has been shown to be an important regulator during the persistent activation process of fibroblasts in fibrotic diseases, including in pulmonary fibrosis, liver fibrosis, renal fibrosis and systemic sclerosis. [30] [31] [32] [33] [34] Evidence for a role of epigenetic modification in keloid disease is now also coming to light.
| EPIGENETIC MECHANISMS IN KELOID SCARRING
| DNA Methylation in keloid scarring
DNA methylation is the most common epigenetic modification.
Methylation refers to a chemical modification process in which a methyl group from adenosyl methionine is transferred to a carbon atom in the cytosine ring of the DNA molecule. This process is catalysed by DNA methyltransferase (DNMT) enzymes. 35, 36 Methylation is most common at CpG dinucleotides. 37 The DNMT family includes three members: DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a) and DNA methyltransferase 3b (DNMT3b).
Although DNMT1 is involved primarily in maintaining DNA methylation status during cell division, a process known as "methylation maintenance", DNMT3a and DNMT3b both modify unmethylated DNA, generating newly methylated bases, a process known as "de novo methylation". 38, 39 Recent reports demonstrated that the expression of TGF-β1, phospho-smad2 and phospho-smad3 were elevated in keloid lesions, while the expression of smad7 was decreased. 40 5-aza-2-deoxycytidine (5-aza-dC), an inhibitor of DNA methyltransferase, appeared to reverse these changes in expression level, suggesting epigenetic control was important. 40 The proportion of apoptotic cells in keloid fibroblasts in culture also can be modulated by the addition of the same methylation inhibitor, again supporting a role for methylation in important cell changes in keloid disease. These studies provide support for a role of DNA methylation in keloid scarring. However, further work will be required to understand the key changes driving pathogenesis amidst the extensive changes that occur as a consequence of keloid progression.
| Histone modification in keloid scarring
Histone modifications are covalent modifications of N-residues in the distal amino acids, including acetylation of lysine (K) residues, ubiquitination of lysine (K) or arginine (R) residues and phosphorylation of serine (S) or threonine (T). 45, 46 Histone deacetylases (HDACs) and histone acetyltransferases (HATs) can influence gene expression via the removal or addition of acetyl groups to histones. 47 Previous studies have found that the use of HDAC inhibitors decreased collagen production in keloid fibroblasts in vitro. 48 HAT inhibition also has an anti-fibrotic effect, and overexpression of p300 (a cofactor with histone acetylase activity) had a significant pro-fibrotic effect in response to TGF-β1 in fibroblasts from scleroderma patients. 
| Non-coding RNAs in keloid scarring
| miRNAs and keloid scarring miRNA expression profiles in keloid scarring
Several miRNAs have been implicated in the process of fibroblast activation (Table 1) . miRNA expression profiles have also been obtained from keloid tissue, fibroblasts and serum (Table 2) . Using miRNA microarrays in 12 pairs of keloid tissue and corresponding normal skin, Liu et al found a total of 32 differentially expressed miRNAs. Among them, 23 miRNAs were up-regulated, while 9 miRNAs were downregulated. 59 In another study, 17 differentially expressed miRNAs were identified in four keloid tissue samples compared to three normal skin samples. 60, 61 Three miRNAs in common were detected in both studies;
has-miR-199a-5p, has-miR-21 and has-miR-214. miRNA expression patterns are evaluated by miRNA PCR array analysis consisting of 88 miRNAs involved in human cell differentiation and development. Sixtyfive miRNAs exhibited abnormal expression in three keloid compared to three normal skin samples. 62 Interestingly, has-miRNA-21 was differentially expressed in all three studies. In the study of Guo XR et al.,
12 differentially expressed miRNAs were screened in human keloids.
However, the abnormal expression of has-miRNA-21 was not found.
63
miRNA expression profiles were further compared between fibroblasts from keloid and normal skin using miRNA microarray analysis.
Nine miRNAs in keloid-derived fibroblasts were different from fibroblasts of normal skin, with six miRNAs including miR-152, miR-23b-3p, miR-31-5p, miR-320c, miR-30a-5p and hsv1-miR-H7, up-regulated and three, including miR-4328, miR-145-5p and miR-143-3p, downregulated. 64 One similar study also found 27 miRNAs were differentially expressed, 7 of which were significantly up-regulated in keloid fibroblasts, and 20 of which were significantly down-regulated.
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A recent study investigated the expression profiles of miRNAs in sera from nine keloid patients and seven normal controls. miRNA microarray analysis identified 37 differentially expressed miRNAs (17 up-regulated and 20 down-regulated) in keloid patients. 66 Some of the key miRNAs that appear differentially expressed in keloid cells are assessed in more detail below.
Pivotal miRNAs in keloid scarring
miR-7 Following on from the microarray data, Etoh M et al.
confirmed the expression of miR-7 was significantly decreased in keloid tissue compared to normal skin by PCR array analysis. 67 In situ hybridization showed that the signal for miR-7 was not evident in the keloid fibroblasts but present in those from normal tissue. miR-7 has been linked to excessive collagen expression in localized scleroderma via the induction of an overexpression of type I collagen.
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However, the role of miR-7 in keloid disease remains unknown. 
| Long non-coding RNA (lncRNA) and keloid scarring
lncRNA can regulate gene expression and is important in the control of the cell cycle and cell proliferation. 81, 82 Recently, using microarray and qRT-PCR approaches, one study identified and validated differential expression of lncRNAs in keloid tissue compared to normal skin. 83 In preliminary screening, 1731 lncRNAs were up-regulated and 782
down-regulated in expression in keloid tissue. Differential expression of mRNAs was also identified. 84 A co-expression network of lncRNA and mRNA was performed and it was found that a lncRNA, calcium voltage-gated channel subunit alpha1 G-antisense 1 (CACNA1G-AS1), was connected to a number of mRNAs that showed differential expression.
Another lncRNA, lncRNA-activated by TGF-β (lncRNA-ATB),
was also observed to be up-regulated in keloid tissue. lncRNA-ATB can regulate the autocrine secretion of TGF-β2 in keloid fibroblasts by inhibiting the expression of zinc finger protein 217 (ZNF217) via miR-200c. 79 Therefore, these findings indicate that a lncRNA-ATB/ miR-200c/ZNF217/TGF-β2 signalling axis may be involved in the initiation and progression of keloid disease.
| CONCLUSION
Epigenetics may provide a new direction for the study of the pathogenesis of keloid scarring. Expression studies have provided support for a role of epigenetic change in keloid disease, and future studies increasing sample number and study power may increase insight into the role of specific changes. There appears to be a role for multiple epigenetic mechanisms in keloid pathogenesis, including DNA methylation, histone modification and regulatory RNA changes. There is also some evidence that epigenetic modification may provide a new therapeutic option, with in vitro studies suggesting drugs that affect epigenetic processes can influence expression and phenotype of keloid cells. However at this stage, our understanding of the key epigenetic changes and their effects is still limited, and therefore clinical intervention will take time. Nevertheless, further work on the role of epigenetic changes in keloid scarring is warranted based on the evidence from the studies conducted to date.
